Research news
Today we publish new statistics about Parkinson’s in the UK, highlighting gaps in NHS services.
A new research trial will start by testing 2 potential treatments that could slow or even stop Parkinson’s getting worse.
HER-096, a potential new Parkinson's treatment, has shown promising phase 1 trial results, proving it’s safe, well-tolerated, and effective in reaching the brain in people with Parkinson's. This is a crucial step towards a drug that could slow, stop, or even repair Parkinson's damage.
As the leading funder of Parkinson’s research in Europe, we’re pleased to announce that we’re supporting new projects that hope to bring us closer to better treatments to transform the lives of those affected by Parkinson’s.
We’ve awarded Cellestial Health £55,000 to continue exploring networks of brain cells that may hold answers for new treatments for Parkinson’s.
Thanks to our crucial funding, a new drug treatment, created by NRG Therapeutics, is moving forwards.
The UK government has published its 10 Year Health Plan for England. We look at what this may mean for people with Parkinson’s and what we think needs to happen next.
We’re launching a project aimed at improving access to specialist mental health services for people with Parkinson's who experience moderate to severe mental ill-health.
11 people have received the treatment which aims to boost brain cells’ ability to repair themselves.
A clinical trial for people with a sleep disorder who are at higher risk of developing Parkinson’s has begun in Oxfordshire.